Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease

NCT07682896 is registered in ClinicalTrials.gov with Yarrow Bioscience, Inc. as lead sponsor.

NCT NCT07682896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07682896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease
Lead sponsor
Yarrow Bioscience, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 10, 2026
Completion date
September 30, 2029
Enrollment
232 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

graves' disease